Viking Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Viking Therapeutics's estimated annual revenue is currently $6.2M per year.
- Viking Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Viking Therapeutics has 31 Employees.
- Viking Therapeutics grew their employee count by 7% last year.
Viking Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Finance and Administration | Reveal Email/Phone |
2 | SVP, Clinical Operations | Reveal Email/Phone |
3 | Director, Clinical Operations | Reveal Email/Phone |
4 | Director Finance and Controller | Reveal Email/Phone |
5 | Senior Director, Pharmaceutical Development | Reveal Email/Phone |
6 | Sr. Director, Pharmaceutical Development | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Senior Director, Pharmacology | Reveal Email/Phone |
9 | Director, Pharmaceutical Development | Reveal Email/Phone |
10 | Senior Manager, Statistical Programming | Reveal Email/Phone |
Viking Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Viking Therapeutics?
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD. See more at http://www.vikingtherapeutics.com
keywords:N/A
N/A
Total Funding
31
Number of Employees
$6.2M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Viking Therapeutics News
During the same quarter in the previous year, the firm posted ($0.15) EPS. On average, analysts expect Viking Therapeutics to post $-1 EPS for...
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX Get Rating) have earned a consensus recommendation of Buy from the nine research firms...
Viking Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego. The company's pipeline is focused on developing...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 31 | N/A | N/A |
#2 | $3.6M | 31 | N/A | N/A |
#3 | $3.6M | 31 | N/A | N/A |
#4 | $4.8M | 31 | 11% | N/A |
#5 | $2.4M | 31 | -6% | $37M |